NRx Pharmaceuticals, Lotus Pharmaceuticals e Alvogen Inc. anunciam colaboração para desenvolver e comercializar o NRX-101 NRx Pharmaceuticals, Lotus Pharmaceuticals e Alvogen irão colaborar no desenvolvimento e comercialização futuros de NRX-101 para tratar a depressão bipolar com tendência suicida resistente ao...

NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101 NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen to collaborate on the further development and commercialization of NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD) for...